Rapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice

Superagonistic CD28-specific monoclonal antibodies (CD28SA) are highly effective activators of regulatory T-cells (Treg cells) in rats, but a first-in-man trial of the human CD28SA TGN1412 resulted in an unexpected cytokine release syndrome. Using a novel mouse anti-mouse CD28SA, we re-investigate the relationship between Treg activation and systemic cytokine release. Treg activation by CD28SA was highly efficient but depended on paracrine IL-2 from CD28SA-stimulated conventional T-cells. Systemic cytokine levels were innocuous, but depletion of Treg cells prior to CD28SA stimulation led to systemic release of proinflammatory cytokines, indicating that in rodents, Treg cells effectively suppress the inflammatory response. Since the human volunteers of the TGN1412 study were not protected by this mechanism, we also tested whether corticosteroid prophylaxis would be compatible with CD28SA induced Treg activation. We show that neither the expansion nor the functional activation of Treg cells is affected by high-dose dexamethasone sufficient to control systemic cytokine release. Our findings warn that preclinical testing of activating biologicals in rodents may miss cytokine release syndromes due to the rapid and efficacious response of the rodent Treg compartment, and suggest that polyclonal Treg activation is feasible in the presence of antiphlogistic corticosteroid prophylaxis.

[1]  J. Bluestone,et al.  Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells , 2009, Immunological reviews.

[2]  P. De Baetselier,et al.  Experimental expansion of the regulatory T cell population increases resistance to African trypanosomiasis. , 2008, The Journal of infectious diseases.

[3]  B. Schraven,et al.  CD28 superagonists: what makes the difference in humans? , 2008, Immunity.

[4]  A. Flügel,et al.  A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. , 2008, The Journal of clinical investigation.

[5]  R. Abe,et al.  Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody can prevent rat cardiac allograft rejection. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[7]  C. Loddenkemper,et al.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease , 2007, The Journal of experimental medicine.

[8]  J. Sprent,et al.  Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease , 2006, Expert opinion on biological therapy.

[9]  Thomas Hanke.  Lessons from TGN1412 , 2006, The Lancet.

[10]  R. Gold,et al.  Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. , 2006, Brain : a journal of neurology.

[11]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[12]  Shimon Sakaguchi,et al.  Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease , 2006, Immunological reviews.

[13]  J. Ortaldo,et al.  Glucocorticoid amplifies IL‐2‐dependent expansion of functional FoxP3+CD4+CD25+ T regulatory cells in vivo and enhances their capacity to suppress EAE , 2006, European journal of immunology.

[14]  D. Altschuh,et al.  Cutting Edge: Monovalency of CD28 Maintains the Antigen Dependence of T Cell Costimulatory Responses1 , 2006, The Journal of Immunology.

[15]  J. Lohr,et al.  Sequential development of interleukin 2–dependent effector and regulatory T cells in response to endogenous systemic antigen , 2005, The Journal of experimental medicine.

[16]  F. Powrie,et al.  Fueling regulation: IL-2 keeps CD4+ Treg cells fit , 2005, Nature Immunology.

[17]  L. Klein,et al.  Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling , 2005, Nature Immunology.

[18]  A. Rudensky,et al.  A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.

[19]  B. Bisikirska,et al.  TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. , 2005, The Journal of clinical investigation.

[20]  R. Gold,et al.  Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis , 2005, The Journal of experimental medicine.

[21]  A. Scheffold,et al.  Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL‐)two to tango , 2005, European journal of immunology.

[22]  Shimon Sakaguchi,et al.  Homeostatic maintenance of natural Foxp3 + CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization , 2005, The Journal of experimental medicine.

[23]  M. Veldhoen,et al.  CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. , 2005, International immunology.

[24]  A. Singer,et al.  CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2 , 2005, Nature Immunology.

[25]  A. Rudensky,et al.  Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. , 2004, Immunity.

[26]  L. Adorini,et al.  Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. , 2004, Seminars in immunology.

[27]  J. Bluestone,et al.  Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4+CD25+ Regulatory T Cells 1 , 2003, The Journal of Immunology.

[28]  J. Lohr,et al.  The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens , 2003, Nature Immunology.

[29]  T. Hünig,et al.  Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist , 2003, European journal of immunology.

[30]  J. Lafaille,et al.  Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell Function , 2002, The Journal of experimental medicine.

[31]  H. Lassmann,et al.  CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation , 2002, Nature Medicine.

[32]  David F. Richards,et al.  In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing Cytokines , 2002, The Journal of experimental medicine.

[33]  T. Hünig,et al.  Control of T cell hyperactivation in IL‐2‐deficient mice by CD4+CD25– and CD4+CD25+ T cells: evidence for two distinct regulatory mechanisms , 2001, European journal of immunology.

[34]  J. Bluestone,et al.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. , 2000, Immunity.

[35]  H. Einsele,et al.  Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. , 1995, Bone marrow transplantation.

[36]  B. Echtenacher,et al.  T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor , 1992, The Journal of experimental medicine.

[37]  I. Horak,et al.  Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting , 1991, Nature.

[38]  P. Vereerstraeten,et al.  RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN‐2, AND GAMMA‐INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL ANTIBODY IN KIDNEY TRANSPLANT RECIPIENTS , 1989, Transplantation.

[39]  T. Hünig.  Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. , 2007, Advances in immunology.

[40]  K. Seeger,et al.  Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature. , 2006, Haematologica.

[41]  Jeffrey A. Bluestone,et al.  CD28 Function: A Balance of Costimulatory and Regulatory Signals , 2004, Journal of Clinical Immunology.

[42]  C. Ferran,et al.  The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation. , 1991, Current topics in microbiology and immunology.